Abstract:ObjectiveTo observe the immune related adverse reactions caused by immune checkpoint inhibitors in 80 patients with advanced malignant tumors. Methods Retrospective analysis was performed on 80 patients with advanced malignant tumor who received immune checkpoint inhibitor treatment in the Third Affiliated Hospital of Anhui Medical University from January 2019 to May 2021. The immune related adverse reactions during the treatment period were observed, including the type, grade, occurrence time, treatment measures and prognosis of adverse reactions. Results Among the 80 patients, 32 patients developed immune treatment-related adverse reactions, with an overall incidence of 40.0% and a median occurrence time of 4.857 weeks, including 14 cases of immunological infusion reaction, 7 cases of immunological dermatitis, 5 cases of immunological thyroid dysfunction, 5 cases of immunological gastrointestinal toxicity and 1 case of immunological pneumonia. The grade 1 or 2 adverse reactions incidence of 96.9%. After symptomatic treatment, hormone shock therapy and maintenance therapy, 31 patients had complete remission of adverse reactions, and 1 patient died of immune pneumonia. Conclusion The incidence of immune-related adverse reactions is high, most of which are grade 1 or 2 adverse reactions. The overall safety is high and the adverse reactions can be tolerated.